Drug Trial Radar · NCT03328026
Combination Study of SV-BR-1-GM With Retifanlimab
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Mar 16, 2018
Primary completion
Mar 24, 2026
Study completion Mar 24, 2026
Sponsor
- Lead sponsor
- BriaCell Therapeutics CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- LumaBridge
- First posted
- Nov 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy. Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3 weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients (dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an expansion cohort of up to 24 patients will be treated with that combination. These will be randomized to two regimens differing in the timing of checkpoint inhibitor administration.
Conditions
- Breast Cancer
- Breast Neoplasm
- Metastatic Breast Cancer
- Breast Cancer Metastatic
Interventions
SV-BR-1-GMBiological
SV-BR-1-GM inoculation intradermally at 4 sites.
Low dose cyclophosphamideDrug
Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
Interferon InoculationDrug
Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
retifanlimabDrug
retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]Time frame: Through study completion, an average of 1 year
- Evaluate the Proportion of Patients with Abnormalities in Safety Laboratory Parameters that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab) [Safety]Time frame: Through study completion, an average of 1 year
- Evaluate changes in the electrocardiogram QT interval that occur in patients treated with SV-BR-1-GM administered in combination with INCMGA00012 (retifanlimab)[Safety]Time frame: Through study completion, an average of 1 year
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California
St. Joseph Heritage Healthcare
Santa Rosa, California
Mayo Clinic Florida
Jacksonville, Florida
University of Miami/Sylvester at Plantation
Plantation, Florida
Carle Cancer Institute
Urbana, Illinois
Cancer Center of Kansas (CCK)
Wichita, Kansas
The Center for Cancer and Blood Disorders a division of American Oncology Partners MD
Bethesda, Maryland
St Vincent-Frontier Cancer Center
Billings, Montana
Nebraska Cancer Specialists
Omaha, Nebraska
Overlook Medical Center Oncology Research, Atlantic Health System
Summit, New Jersey
Manhattan Hematology Oncology Associates (MHOA)
Manhattan, New York
Mary Crowley Cancer Research
Dallas, Texas
Tranquil Clinical Research
Webster, Texas
Hematology-Oncology Associates of Fredericksburg, Inc
Fredericksburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.